| pubmed-article:16631355 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16631355 | lifeskim:mentions | umls-concept:C0162783 | lld:lifeskim |
| pubmed-article:16631355 | lifeskim:mentions | umls-concept:C0036341 | lld:lifeskim |
| pubmed-article:16631355 | lifeskim:mentions | umls-concept:C0005586 | lld:lifeskim |
| pubmed-article:16631355 | lifeskim:mentions | umls-concept:C0040648 | lld:lifeskim |
| pubmed-article:16631355 | lifeskim:mentions | umls-concept:C1417836 | lld:lifeskim |
| pubmed-article:16631355 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:16631355 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16631355 | pubmed:dateCreated | 2006-5-22 | lld:pubmed |
| pubmed-article:16631355 | pubmed:abstractText | Abnormal cortical and subcortical dopaminergic activities are among the most consistent neuropathological findings in schizophrenia. The molecular mechanisms remain unspecified. NGFI-B and Nurr1 are two closely related transcription factors involved in dopaminergic cell differentiation, maturation, and apoptosis. NGFI-B knockout mice show attenuated behavioral response to dopamine receptor agonists, whereas Nurr1 knockout disrupts midbrain dopaminergic neuron development. To further understand the role of Nurr1 and NGFI-B in schizophrenia and bipolar disorders, we measured Nurr1 and NGFI-B mRNA in the prefrontal cortex Brodmann's areas 9 (BA 9) and BA 46 by in situ hybridization, and the protein levels in BA 9 by Western blotting, of patients with schizophrenia, major depression, and bipolar disorders, and non-psychiatric control subjects (n=15 per group). NGFI-B mRNA (P<0.05) and protein (P<0.01) were significantly lower in patients with schizophrenia (BA 9), and NGFI-B mRNA was lower in bipolar disorder (BA 9 and BA 46) than in the controls. In the deep cortical layers of BA 46, Nurr1 mRNA was significantly (P<0.05) lower in patients with bipolar disorder and schizophrenia than in the controls. Nurr1 protein in BA 9 was significantly lower in major depression (P<0.05) and lower at a trend level in schizophrenia (P=0.056) than in the controls. These data show a deficient prefrontal NGFI-B and Nurr1 expression in schizophrenia and bipolar disorder. Further study may elucidate if and how these deficiencies could be associated with abnormal dopaminergic functions seen in both illnesses. | lld:pubmed |
| pubmed-article:16631355 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16631355 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16631355 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16631355 | pubmed:month | May | lld:pubmed |
| pubmed-article:16631355 | pubmed:issn | 0920-9964 | lld:pubmed |
| pubmed-article:16631355 | pubmed:author | pubmed-author:ZhangLeiL | lld:pubmed |
| pubmed-article:16631355 | pubmed:author | pubmed-author:XingGuoqiangG | lld:pubmed |
| pubmed-article:16631355 | pubmed:author | pubmed-author:PostRobertR | lld:pubmed |
| pubmed-article:16631355 | pubmed:author | pubmed-author:RussellShaniS | lld:pubmed |
| pubmed-article:16631355 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16631355 | pubmed:volume | 84 | lld:pubmed |
| pubmed-article:16631355 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16631355 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16631355 | pubmed:pagination | 36-56 | lld:pubmed |
| pubmed-article:16631355 | pubmed:dateRevised | 2010-9-2 | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:meshHeading | pubmed-meshheading:16631355... | lld:pubmed |
| pubmed-article:16631355 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16631355 | pubmed:articleTitle | Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders. | lld:pubmed |
| pubmed-article:16631355 | pubmed:affiliation | Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799, USA. gxing@usuhs.mil | lld:pubmed |
| pubmed-article:16631355 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16631355 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16631355 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16631355 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16631355 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16631355 | lld:pubmed |
